New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 28, 2014
16:13 EDTACT, TKPYYActavis confirms patent challenge on generic Colcrys
Actavis (ACT) confirmed that it has filed an Abbreviated New Drug Application with the U.S. FDA seeking approval to market Colchicine Tablets USP, 0.6 mg. Actavis' ANDA product is a generic version of Takeda's (TKPYY) Colcrys, which is a prescription medicine used in adults to prevent and treat gout flares. Takeda Pharmaceuticals U.S.A. filed suit against Actavis on February 27 in the U.S. District Court for the District of Delaware seeking to prevent Actavis from commercializing its ANDA product prior to the expiration of certain U.S. patents. The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Actavis' ANDA for up to 30 months from the date the plaintiffs received notice of Actavis' ANDA filing or until final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.
News For ACT;TKPYY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
09:39 EDTACTPerrigo in exclusive talks to buy Omega Pharma, Bloomberg says
Subscribe for More Information
09:18 EDTACTPerrigo in exclusive talks to buy Omega Pharma, Bloomberg says
Subscribe for More Information
October 27, 2014
19:48 EDTTKPYYEli Lilly responds to ruling in Takeda case
Eli Lilly (LLY) issued the following statement in response to a judge's ruling that the punitive damages awarded in the case of Terrence Allen, et al. v. Takeda Pharmaceuticals (TKPYY) be reduced. The judge reduced the punitive damages from $3B for Lilly and $6B for Takeda to $9.2M for Lilly and $27.6M for Takeda. Plaintiffs also were awarded $1.27M in compensatory damages. The allocation of liability was 75% Takeda, 25% Lilly. "While we have empathy for the plaintiff, we believe the evidence did not support his claims," said Mike Harrington, senior VP and general counsel, Lilly. "We will continue working vigorously to overturn the verdict."
18:45 EDTTKPYYTakeda Pharmaceutical Co. Ltd. reponds to ruling in diabetes drug case
Subscribe for More Information
17:31 EDTTKPYYEli Lilly, Takeda have Actos award cut to $36.8M from $9B, Bloomberg reports
Subscribe for More Information
15:18 EDTACTEarnings Preview: Pfizer looks to new products to offset generic competition
Subscribe for More Information
10:36 EDTACTAllergan delivers earnings beat, says willing to consider higher Valeant bid
Subscribe for More Information
October 23, 2014
18:18 EDTACTGlenview Capital acquires stake in Actavis, Bloomberg reports
Subscribe for More Information
08:10 EDTACTActavis confirms appeals court upholds Lo Loestrin Fe patent
Subscribe for More Information
October 22, 2014
08:38 EDTACTActavis signs option to acquire Rhythm Health
Subscribe for More Information
October 21, 2014
06:44 EDTACTActavis among bidders for Omega Pharma, Bloomberg reports
Subscribe for More Information
October 20, 2014
18:51 EDTACTOn The Fly: After Hours Movers
Subscribe for More Information
06:28 EDTACTAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 17, 2014
09:47 EDTACTValeant will not raise Allergan bid ahead of record date, CNBC reports
Valeant (VRX) will not raise its hostile takeover bid for Allergan (AGN) ahead of the record date for the vote, CNBC's David Faber reports. Allergan (AGN) is not currently in takeover talks with Actavis (ACT), Faber added.
09:45 EDTACTAllergan not in deal talks with Actavis, CNBC reports

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use